

SOUTHWEST VIRGINIA PRESCRIPTION DRUG ABUSE SUMMIT

DEA Washington Division Diversion Control Program

Mary Johnson-Rochee
Diversion Program Manager
November 14, 2012



- DEA's Diversion Mission
- How DEA's Diversion Mission is Accomplished
- Controlled Substances Act
- DEA's Registration System
- DEA's Registrant Population
- Diversion Control Program
- Initiative to Address Controlled Substance Diversion
- Washington Field Division Diversion Workforce
- Trends and Traffic Commonly Abused/Diverted Drugs
- Accomplishments and Investigative Activities
- Questions and Comments

Mission of DEA's Diversion Control Program

- Ensure an adequate and uninterrupted supply of pharmaceutical controlled substances and listed chemicals to meet legitimate medical, scientific and commercial needs.
- Prevent, detect and investigate the diversion of these substances into illicit channels.


Washington Division Diversion Offices and Positions



Controlled Substances Act

Comprehensive Drug Abuse Prevention and Control Act (1970)

- Common Name: Controlled Substances Act of 1970 (CSA)
- Replaced more than 50 pieces of drug control legislation
- Established a single system of control for both narcotics and psychotropic drugs
- Established five schedules that classified controlled substances according to their properties



Controlled Substances Act (Continued)

Comprehensive Drug Abuse Prevention and Control Act (1970)

- Established a "closed system" that tracks and accounts for controlled substances from import or manufacture through wholesale distribution to the ultimate end-user
- Facilitated the creation of the Compliance Program (1971) now renamed as the Office of Diversion Control to monitor all aspects of legitimate manufacture and distribution of controlled substances

DEA Registration: A Cornerstone of the CSA

- Every person or entity that handles controlled substances must be registered or be exempt by regulation from registration
- Must apply using the appropriate DEA form for the designated business activity and pay the required fee, unless fee exempt
- Must meet state licensure requirements in state(s) where business is conducted
- Must be in good standing and comply with DEA requirements



How DEA's Diversion Mission is Accomplished

- Registration of Legitimate C/S and List 1 Handlers
- Scheduled Investigations
- Liaison with S&L and Federal Regulatory, Law Enforcement and Industry Counterparts
- Monitoring of Trends and Traffic Data
- Focused Proactive & Reactive Initiatives
- Administrative, Civil and Criminal Efforts (Divisional and Multi-Jurisdictional)
- Support of DEA Components
- Focused DEA Enforcement & Intelligence Support



Virginia's DEA Registrant Population

Total Population: 38,569 (As of November 2012)

Total US Population: 1,458,650


 Practitioner 	-	30,111
 Mid-Level Practitioner 	-	6,181
Pharmacy	-	1,602
 Hospital/Clinic 	-	351
 Manufacturer 	-	6
 Distributor 	-	17
 Reverse Distributor 	-	0
 Researcher 	-	117
 Teaching Institution 	-	9
 Analytical Lab 	-	37
 Importer 	-	3
 Exporter 	-	5
 Narcotic Treatment Prog. 	-	22




DEA Monitoring and Tracking Mechanisms

- Scheduling of controlled substances (C/S)
- Registration of C/S handlers
- Recordkeeping/Accountability
- Required Reports Submitted to DEA by Registrants
- Security requirements
- Manufacturing quotas
- DEA CSA2 Database

Monitoring DEA's Closed System



Sosed System of Distribution



Points of Penetration within the "Closed System"

- Practitioners
 - illegal distribution
 - self abuse
- Pharmacists
 - illegal distribution
 - self abuse
 - internet diversion
- Employee pilferage
 - hospitals
 - practitioners' offices
 - nursing homes
 - retail pharmacies
 - manufacturing/distribution facilities
- Diversion by "Patients"
 - individual(s)
 - organized drug rings





Tools for Addressing Diversion of Controlled Substances

- Regulatory Action
- Administrative Action
- Civil
- Criminal



DEA Initiatives to Address C/S Abuse and Diversion

- Tactical Diversion Squads
- State Rx Drug Monitoring Programs
- Regulatory Oversight to Drug Treatment Providers
- Liaison w/Regulatory and Law Enforcement, Internet Providers, and the Pharmaceutical Industry to address Regulatory Compliance and prevent Diversion
- Internet Public Service Announcements
- Educational Outreach Efforts to Health Professionals, Academia, Counterparts, General Public and other Stakeholders

Most commonly abused pharmaceuticals throughout the Division:

Oxycodone products
Hydrocodone
Methadone
Benzodiazepines (Xanax, Klonopin)

Drug to Watch: Buprenorphine (Subutex and Suboxone)



DEA Diversion – Front and Center

Focused regulatory efforts directed at ensuring full DEA Registrant compliance (more frequent and in-depth DEA regulatory inspections)

- Community Outreach re: Diversion/Abuse of Pharmaceuticals
- Active support by to support the passage of legislation to establish PDMPs in all states
- Active DEA engagement in national civil initiatives targeting DEA Registrants found to be in violation of the CSA
- Immediate Suspension Orders issued to DEA Registrants involved in large volume negligent Distribution/Diversion of highly abused/diverted controlled substance products
- DEA representation in regional Pharmaceutical Drug Summits to address the growing Rx drug abuse epidemic
- Several Orders to Show Cause issued to deny, suspend or revoke the DEA registrations of violative DEA registrants
- Hosting of Nat'l Drug Take Back Initiatives to address proper disposal of unwanted/expired drugs in the community.





Office of Diversion Control

Contact Us | Site Map | Search

Registration

Reporting

Info & Legal Resources

Inside Diversion Control



The voice in Federal decision-making



To view PDF documents



External links included in this website should not be construed as an official endorsement of the views contained therein.

Haiti Disaster Relief

Click Here



What's New

Mylan Pharmaceuticals Inc. (April 26, 2010)

Almac Clinical Services Inc. (April 26, 2010)

Q&A For Prescribing Practitioners Q&A For Pharmacies

Q&A For Providers of Electronic Prescription Applications, Pharmacy Applications, and Intermediaries

Noramco, Inc - Correction (April 20,

Varian Inc. (April 16, 2010)

Siemens Healthcare Diagnostics Inc. (April 16, 2010)

Mylan Pharmaceuticals Inc. (April 16, 2010)

Lipomed, Inc. (April 16, 2010)

60-Day Notice of Information Collection Under Review - Proposed Collection; Comments Requested:

Registration Support

Registration Number Toll Free: 1-800-882-9539

Save time by applying for and/or renewing your DEA Registration online. Data will be entered through a secure connection to the ODWIF online web application system.

Minimum requirements:

Credit Card and a web browser that supports 128-bit encryption.

Email Registration Questions to DEA.Registration.Help@usdoj.gov

Field Offices with Registration Specialists

Quick Links

Renew Applications Online

New Application Online

Duplicate Certificate Request

Registration Validation

Registration Change Request

Order Forms

CSOS

DEA Form 106: Report Theft or Loss of Controlled Substance

Combat Meth Act 2005

Cases Against Doctors

Mailing Addresses for Topics Related to Title 21 CFR

Electronic Prescriptions for Controlled Substances

FAQ

ARCOS

Controlled Substance Ordering System (CSOS)

DEA Form 222 Order Forms

Electronic Prescriptions for Controlled Substances

General Information

Issuance of Multiple Prescriptions for Schedule II Controlled Substances

ug Monitoring

www.deadiversion.usdoj.gov

Drug Enforcement Administration Home





QUESTIONS AND ANSWERS